Trending...
- Slotozilla Reports Strong Growth in Q2 2026
- Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
- LCC Asia Pacific Sponsors CubeSatPlus 2026 at UNSW Sydney
PHILADELPHIA, Nov. 9, 2023 ~ Suvoda LLC, a leading global clinical trial technology company, has successfully conducted usability testing of its electronic clinical outcomes assessment (eCOA) solution in collaboration with RWS Life Sciences. The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.
The findings from the RWS Life Sciences usability testing effort will be presented in a paper titled "Solidifying Usability Testing Guidelines for eCOAs from the Patient Perspective" at ISPOR Europe 2023, to be held in Copenhagen, Denmark, November 12-15. The focus group consisted of oncology patients using smartphone and tablet devices. These patients represented a variety of conditions related to their cancer diagnoses, including difficulties with gripping and reading, as well as concentration and tactile challenges. The study, which included participants ranging from ages 18 to 75, was qualitative in nature and adhered to best practices in user experience research.
More on The PennZone
Chryso Hadjidemetriou, PhD with RWS Life Sciences said "Patient-centered usability testing is valuable because it focuses on whether patients can interact with the eCOA efficiently and effectively, particularly in cases where participants may experience physical or visual accessibility challenges." He further added that "The qualitative and patient-centered process of usability testing helps to measure operational efficacy of the eCOA system; recognize design issues causing patient dissatisfaction and impeding data collection; examine software and working improvements; and understand and evaluate user interaction, with an end-goal of improving the users' experience."
Nearly all participants in the focus group found Suvoda eCOA to be easy to navigate, intuitive, clear, and well-designed. They appreciated the ease of moving through the questionnaire screens, clear instructions, and the flexibility to change answers as needed. Catherine Munera vice president of biometrics for Cara Therapeutics said "Patient-reported outcome (PRO) data is crucial in clinical studies so it's imperative to have data capture tools that are easy for patients to use and manage with minimal intervention from clinical sites." She further added that "Suvoda eCOA was incredibly easy for our patients to use; we had an increase in patient compliance in completing PRO questionnaires as compared to previous studies with other eCOA providers."
More on The PennZone
The usability testing process was conducted in accordance with current industry standards and FDA guidance to ensure the highest level of quality and compliance. Andrés Escallón vice president Suvoda eCOA practice said "Suvoda put the user experience at the center of product development so sites can focus time on patients and not on technology." He further added that "This study validates that our eCOA solution makes it easy and efficient to obtain quality patient outcomes data for submissions and approvals."
Suvoda announced general availability of its eCOA product back in May 2023 which addresses difficulties associated with traditional eCOA products by delivering simplified questionnaire licensing & localizations along with streamlined device logistics. Additionally since Suvoda's solution delivers IRT & Econsent on a single platform it helps improve data integrity & study teams benefit from improved data integrity.
The findings from the RWS Life Sciences usability testing effort will be presented in a paper titled "Solidifying Usability Testing Guidelines for eCOAs from the Patient Perspective" at ISPOR Europe 2023, to be held in Copenhagen, Denmark, November 12-15. The focus group consisted of oncology patients using smartphone and tablet devices. These patients represented a variety of conditions related to their cancer diagnoses, including difficulties with gripping and reading, as well as concentration and tactile challenges. The study, which included participants ranging from ages 18 to 75, was qualitative in nature and adhered to best practices in user experience research.
More on The PennZone
- RemoteBridge Names Dr. John N. Just, Ed.D. Chief Executive Officer
- Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History
- New Analysis Details Three Converging Forces in AI and Workforce Policy Behind a $37 Billion GDP Reduction
- Grace Montessori School Earns Prestigious American Montessori Society Accreditation
- Revenue Optics Launches Pricing and Revenue Growth Management Practice, Names Shafohi Alamgir Vice President
Chryso Hadjidemetriou, PhD with RWS Life Sciences said "Patient-centered usability testing is valuable because it focuses on whether patients can interact with the eCOA efficiently and effectively, particularly in cases where participants may experience physical or visual accessibility challenges." He further added that "The qualitative and patient-centered process of usability testing helps to measure operational efficacy of the eCOA system; recognize design issues causing patient dissatisfaction and impeding data collection; examine software and working improvements; and understand and evaluate user interaction, with an end-goal of improving the users' experience."
Nearly all participants in the focus group found Suvoda eCOA to be easy to navigate, intuitive, clear, and well-designed. They appreciated the ease of moving through the questionnaire screens, clear instructions, and the flexibility to change answers as needed. Catherine Munera vice president of biometrics for Cara Therapeutics said "Patient-reported outcome (PRO) data is crucial in clinical studies so it's imperative to have data capture tools that are easy for patients to use and manage with minimal intervention from clinical sites." She further added that "Suvoda eCOA was incredibly easy for our patients to use; we had an increase in patient compliance in completing PRO questionnaires as compared to previous studies with other eCOA providers."
More on The PennZone
- Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
- CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards
- NaturismRE expands international research programme with Health & Wellbeing Survey
- L2 Aviation and Gotonomi Extend UAV Connectivity Beyond Cellular Reach
- LATO AI Solidifies Future in Pittsburgh with North Shore Headquarters
The usability testing process was conducted in accordance with current industry standards and FDA guidance to ensure the highest level of quality and compliance. Andrés Escallón vice president Suvoda eCOA practice said "Suvoda put the user experience at the center of product development so sites can focus time on patients and not on technology." He further added that "This study validates that our eCOA solution makes it easy and efficient to obtain quality patient outcomes data for submissions and approvals."
Suvoda announced general availability of its eCOA product back in May 2023 which addresses difficulties associated with traditional eCOA products by delivering simplified questionnaire licensing & localizations along with streamlined device logistics. Additionally since Suvoda's solution delivers IRT & Econsent on a single platform it helps improve data integrity & study teams benefit from improved data integrity.
0 Comments
Latest on The PennZone
- 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
- Tina Hasselbusch, Turnstone Creative Co-founder and Chief Executive Officer, Named to LVB 300
- Pittsburgh Family Law Attorneys at Pollock Begg Earn Top Honors in 2027 Best Lawyers Guide
- Independent Colbert Packaging Thrives Amid Industrywide Consolidation
- Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
- Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
- Slotozilla Reports Strong Growth in Q2 2026
- Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
- Philadelphia's Girls Anthem to Host The Locker Room Experience Pop-Up for Young Women
- Flexible Plan Investments Names Carl Resnick President
- Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
- Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
- No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
- The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
- Sharon Pinkenson Chosen as Philly Girl Top 40 Winner
- Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
- FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
- Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
- Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
- San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only